5-Fluorouracil Enhances the Anti-Tumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers

Investigators report that the glutaminase inhibitor CB-839 preferentially inhibited xenograft growth of PIK3CA-mutant, but not wild-type, colorectal cancer. Moreover, the combination of CB-839 and 5-fluorouracil induces PIK3CA-mutant tumor regression in xenograft models.
[Cancer Research]
Abstract
Bookmark

No account yet? Register

0
Share

PRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute Leukemia

The Leukemia & Lymphoma Society and PRA Health Sciences announced a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
[The Leukemia & Lymphoma Society (PRNewswire,LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients

Celularity announced that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells for the treatment of adults with COVID-19 as part of a national clinical trial.
[Celularity Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase II Trial for Immune Mediated Complications in COVID-19 Patients

INmune Bio, Inc. announced that the FDA has accepted the company’s Investigational New Drug application to initiate a Phase II clinical trial evaluating Quellor™, a selective soluble tumor necrosis factor inhibitor, for the treatment of immune mediated complications in COVID-19 patients.
[INmune Bio, Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial

Madrigal Pharmaceuticals, Inc. announced that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed using non-invasive assessments.
[Madrigal Pharmaceuticals, Inc. (GlobeNewswire)]
Press Release
Bookmark

No account yet? Register

0
Share

UroGen Pharma Announces Update on the Phase II Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (OnabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence

UroGen Pharma Ltd. has announced that the Phase II APOLLO clinical trial of a RTGel hydrogel formulation in combination with BOTOX® (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder and urinary incontinence did not meet the primary endpoint
[UroGen Pharma Ltd. (Businesswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Classical and Non-Classical Progesterone Signaling in Breast Cancers

Investigators attempt to understand the classical and non-classical signaling role of progesterone in breast cancers because both nuclear and membrane receptors could become viable therapeutic options for breast cancer patients.
[Cancers]
Pedroza, D. A., Subramani, R., & Lakshmanaswamy, R. (2020). Classical and Non-Classical Progesterone Signaling in Breast Cancers. Cancers, 12(9), 2440. https://doi.org/10.3390/cancers12092440 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Human Serum Albumin as a Clinically Accepted Cell Carrier Solution for Skin Regenerative Application

Researchers investigated four candidate solutions for transporting human keratinocytes.
[Scientific Reports]
Shahin, H., Elmasry, M., Steinvall, I., Markland, K., Blomberg, P., Sjöberg, F., & El-Serafi, A. T. (2020). Human serum albumin as a clinically accepted cell carrier solution for skin regenerative application. Scientific Reports, 10(1), 14486. https://doi.org/10.1038/s41598-020-71553-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

Natera, Inc. announced a collaborative agreement with Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib for the treatment of ER-positive breast cancer, the first circulating tumor DNA based study of a CDK4/6 inhibitor in ER-positive early stage breast cancer.
[Natera, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Chimeric Antigen Receptor-Modified T Cells Targeting EphA2 for the Immunotherapy of Pediatric Bone Tumors

Investigators tested human erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 directed CAR T cells for their capacity to target and kill human paediatric osteosarcoma and Ewing sarcoma tumour cells using in vitro and in vivo assays.
[Cancer Gene Therapy]
Full Article
Bookmark

No account yet? Register

0
Share

Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial

Pluristem Therapeutics, Inc. announced FDA has cleared the Company’s Expanded Access Program for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19 outside of the Company’s ongoing Phase II COVID-19 study in the US.
[Pluristem Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share